China Chemical Raw Exports Decline Curve Presents
August cumulative increase of 24%, September 20% October 17% November 13%% of expected on December 9 … … This is a domestic focus Export of bulk drugs Enterprises in August 2008 after a group of foreign export growth data, this set of data from one side of the true depiction of the world in September 2008 Financial Since the outbreak of the crisis of Chemical API Exports decline curve. Entered since 2009, shrinking international demand, export poor, fought in the domestic international competition, most companies choose rational “resistance-type defense policy,” but Chemical industry Prices remained low, the export tax rebate rate, interest rate … … almost all of the factors are pointing to “bargains”, price cuts seem inevitable.
Domestic competition, international, international competition has always been a country of manufacturing enterprises in China to participate in international trade of chronic illness. In recent years, “China bought from abroad, what, what the prices; China to sell abroad and what they have on the cheap” has become a practice, iron ore, non-ferrous metals has been true. This dilemma can not be repeatedly in China Medicine Industry repeat, otherwise not only hurt the export of many pharmaceutical companies, as well as China, the world pharmaceutical manufacturing country’s image and competitiveness. There is no doubt that we urgently need to expand the current medical needs, especially domestic demand.
Rural and urban communities with the rise of the terminal, basic drugs and speeding up the country to strengthen primary health care service system, increase input in the basic health care, expansion of domestic Chinese demand is expected to more than 200 billion yuan, except overlapping factors, the total is considerable. The expansion will inevitably lead to essential drugs increased demand for bulk drugs. Expanding domestic demand, there are four key tasks: grasping human drug market to consolidate with one hand and market development, veterinary medicine, one hand tapping the potential of traditional varieties of advantages, one hand and characteristics of the species and the development of drug patents expire.
Energetically open up new markets overseas Sell Focus. Asia, Europe and North America has always been a traditional Chinese medicine raw materials and key export markets, three markets total market share of 88.9%. In the current financial turmoil, Europe, North America and other regions hardest hit is the economic downturn. A considerable portion of these regions decreased the purchasing power of customers, some delayed shipments of some to cancel the contract, more is waiting to see lower prices or formation of confrontation with the domestic manufacturers. In Russia, Eastern Europe, Africa and other emerging markets, after market cultivation in recent years, these regions of gradually increasing demand for bulk drugs, if effective measures, the potential of these markets and considerable stamina.
Offer limited production the industry is also a good way. Occupy in the larger international market share, manufacturers are concentrated penicillin industrial salt, Vitamin , Antipyretic and analgesic drugs such as bulk raw material, if properly coordinated operation, or as much as possible while maintaining a high price have both at home and abroad, which is most of the profit bulk drug business insurance jobs a top priority.
More important is the external force by the current economic crisis push, turn crises into opportunities, accelerate industrial upgrading. Raising the technological level, extend the industrial chain of production and export more high value-added, highly competitive, low power consumption, low pollution features of products, which is to free themselves from brutal competition, a great magic weapon, but also the scientific development of pharmaceutical enterprises the only way. This regard, Japan is our model. Of the last century 50’s to 70’s, Japan Zengyin rapid economic growth, increased demand triggered a global non-ferrous metal prices soaring. As Japanese companies in the industrial chain, industrial spare no effort and so, a substantial increase in value-added products, offset the adverse impact of price increases. In exports, domestic do down their opponents, who are our pharmaceutical companies to participate in international competition, the old road. The new situation and new challenges, new thinking, the old road has new life. Exercise to fight the world economic crisis, pose serious threats at the same time also brought a unique opportunity. Is to break the old order, the time to do something.
I am a professional writer from China Computer Parts, which contains a great deal of information about mattings , funny door mats, welcome to visit!
Processing your request, Please wait....
